Stockwinners Market Radar for April 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:01 EDT Cango authorizes up to $50M share repurchase program - Cango said its board of directors has authorized a new share repurchase program under which the company may repurchase up to $50M worth of its outstanding American depositary shares, each representing two Class A ordinary shares, and/or Class A ordinary shares over the next 12 months starting from April 25, 2022.

17:02 EDT Allarity receives Nasdaq noncompliance notification - Allarity Therapeutics announced that on April 20, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, with the Securities and Exchange Commission. This notification has no immediate effect on the listing of the company's common stock on the Nasdaq. However, if the company fails to timely regain compliance with the Nasdaq Listing Rule, the company's common stock will be subject to delisting from Nasdaq. Under the Nasdaq rules, the company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If Nasdaq accepts the company's plan, then Nasdaq may grant the company up to 180 days from the prescribed due date for filing the Form 10-K to regain compliance. If Nasdaq does not accept the company's plan, then the company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.

16:47 EDT SharpLink Gaming receives Nasdaq notice of deficiency - SharpLink Gaming announced that it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the company that it is no longer in compliance with the minimum Market Value of Listed Securities set forth in Nasdaq Marketplace Rule 5550(b)(2) or the alternative criteria for continued listing on the Nasdaq Capital Market. This notice has no immediate action regarding the company's listing or trading of the company's stock. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(C), the company has 180 calendar days, or until October 17, 2022, to regain compliance. If at any time during the compliance period the company's MVLS closes at $35M or more for a minimum of ten consecutive business days, Nasdaq will provide SharpLink with written confirmation of compliance and this matter will be closed. The company believes it is currently in compliance with Nasdaq continued standards under the alternative minimum stockholders' equity standard as defined in Nasdaq Marketplace Rule 5550(b)(1). Management believes it will be able to demonstrate such compliance upon the filing of its audited financial results for the year ended December 31, 2021 on Form 20-F, expected to be filed timely with the U.S. Securities and Exchange Commission.

16:36 EDT Block CEO Jack Dorsey has title changed to 'Block Head and Chairperson' - On April 20, at his request, Jack Dorsey's title changed from "Chief Executive Officer, President and Chairperson" to "Block Head and Chairperson," effective immediately. There will be no changes in Dorsey's roles and responsibilities, and he will continue to serve as principal executive officer of the company.

16:14 EDT Springwater Special Situations receives Nasdaq noncompliance notification - Springwater Special Situations Corp., a blank check company formed for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities, announced that on April 19, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market advising the company that the company did not comply with NASDAQ's Listing Rule 5250(c)(1) for continued listing because NASDAQ had not received the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. NASDAQ had informed the company that it had until June 18, 2022 to submit a plan to regain compliance with respect to this delinquent report. If NASDAQ had approved the company's plan, it would have had the discretion to grant the company an extension of up to 180 calendar days from the due date of the Form 10-K, or until October 12, 2022 to regain compliance. On April 21, 2022, the company filed the Form 10-K with the Securities and Exchange Commission and on April 22, 2022 was notified by NASDAQ that it had regained compliance with NASDAQ's listing rules as a result thereof.

16:12 EDT WW announces organizational realignment, sees $18M-$22M in restructuring charges - According to a regulatory filing, on April 19, 2022, WW International committed to a restructuring plan consisting of (i) an organizational realignment to simplify the company's corporate structure and reduce associated costs and (ii) a continued rationalization of its real estate portfolio resulting in the termination of certain of the company's operating leases. In connection with the 2022 Restructuring Plan, the company anticipates recording restructuring charges which it currently estimates will range between $18M-$22M in the aggregate. The Organizational Realignment will result in the elimination of certain positions and termination of employment for certain employees worldwide. In connection with its Organizational Realignment, the company anticipates recording charges of approximately $12M-$16M in the aggregate with respect to employee termination benefit costs, the majority of which will be recorded in the second quarter of fiscal 2022. In connection with the termination of certain of its operating leases, the company anticipates recording charges of approximately $6M in the aggregate consisting of lease termination and other related costs, the majority of which will be recorded in the second quarter of fiscal 2022. Substantially all of these costs arising from the 2022 Restructuring Plan are expected to result in cash expenditures related to separation payments, other employee termination expenses, and lease termination payments. The company expects the 2022 Restructuring Plan to be fully executed by the end of fiscal 2023.

16:03 EDT Puhui Wealth receives noncompliance notification from Nasdaq - Puhui Wealth announced that the company had received a notification letter from the Listing Qualifications Department of Nasdaq regarding a failure to meet Nasdaq's minimum bid price requirements. The notification letter informed the company that the minimum closing bid price per share for its ordinary shares was below $1.00 for a period of 30 consecutive business days and that the company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550. This press release is issued pursuant to Nasdaq Listing Rule 5810, which requires prompt disclosure of receipt of a deficiency notification.

15:37 EDT Bed Bath & Beyond up 11% after WSJ report on buyout interest for baby unit

13:57 EDT Twitter tests ability to turn captions for videos off/on with 'CC' button - Twitter said it is testing the option to turn captions on or off with a new "CC" button. "Video captions or no captions, it's now easier to choose for some of you on iOS, and soon on Android," the company said. "On videos that have captions available, we're testing the option to turn captions off/on with a new "CC" button." Reference Link

13:34 EDT Air Products to team with World Energy on $2B sustainable aviation fuel project - Air Products announced that it is teaming up with World Energy to build a new $2B expansion project at World Energy's Sustainable Aviation Fuel, or SAF, production and distribution hub in Paramount, California. "The LA county facility is the world's first commercial scale and North America's only SAF production facility and its total fuel capacity will be expanded to 340 million gallons annually. The long-term, take-or-pay agreement with World Energy includes Air Products' construction and ownership of a new hydrogen plant to be operated by Air Products and renewable fuels manufacturing facilities to be operated by World Energy. The project is scheduled to be onstream in 2025 and continues Air Products' leadership in driving the energy transition through world-scale projects," Air Products stated. "This is another world-scale, history-making energy transition project for Air Products one that showcases our onsite offerings and will again demonstrate our large project construction capabilities. It will also enhance the value of our existing hydrogen pipeline in Southern California as we increase our supply capacity with the connection to the new hydrogen production facility we will build in Paramount," added Dr. Samir J. Serhan, Air Products' Chief Operating Officer.

13:29 EDT Creatd says Nasdaq hearings panel to permit continued listing - Creatd announced that it has received the decision of the hearings panel of The Nasdaq Capital Market advising the company that the panel determined to permit the continued listing of the company's securities on the exchange, subject to the company disclosing shareholders' equity of at least $2.5M as of March 31, 2022 in its Form 10-Q and disclosing the successful completion of fund-raising activities and the company's long-term compliance with the exchange's continued listing requirements in a Form 8-K on or before August 29. CEO Laurie Weisberg said, "We are looking forward to executing upon our previously-stated regulatory, operational, and business objectives. We are grateful that the Nasdaq has granted us the opportunity to do so."

12:53 EDT Guess says all four director nominees re-elected by shareholders - Guess announced that based on preliminary vote results provided by its proxy solicitor following its annual meeting, shareholders voted to re-elect all four of its director nominees - Anthony Chidoni, Cynthia Livingston, Maurice Marciano and Paul Marciano - to the company's board. Guess said: "The Guess Board and management team greatly appreciate the engagement we have had with our shareholders throughout this process and the various perspectives shared. Importantly, in our conversations, shareholders have recognized that Guess' clearly defined transformation plan to elevate the Guess and Marciano brands, redefine the Company's global e-commerce strategy, optimize our store footprint, enhance our supply chain, and drive efficiencies across the business is driving positive momentum and meaningful financial results...The Board and management team remain focused on advancing Guess' momentum, executing our transformation strategy and driving long-term growth and value creation. We will continue to engage with our shareholders, and we remain steadfast in our commitment to acting in the best interest of the Company and all Guess shareholders. The Board of Directors takes its fiduciary duties very seriously, believes in due process and will continue to make its decisions based on factual findings."

12:06 EDT AMC to install laser projectors in 3,500 U.S. auditoriums through 2026 - AMC Theatres announced an exclusive agreement between AMC and Cinionic, the Barco cinema joint venture, to "significantly upgrade" the on-screen presentation at 3,500 auditoriums throughout the United States. "Laser at AMC reinforces AMC as the leader in premium theatrical exhibition experiences and signals a significant AMC commitment to the future of movie-going, on-screen presentation, and the company's dedication to Make Movies Better. The move to laser projection offers a more environmentally friendly way to present movies with less waste, including the elimination of replacing xenon bulbs, and a significant reduction in energy usage. Later this year, AMC and Cinionic will begin installing laser projectors in AMC auditoriums around the country on a market-by-market basis, with the full initiative expected to be completed by the end of 2026. The laser projection equipment and associated auditorium enhancements powering Laser at AMC in the 3,500 auditoriums is valued at around a quarter of a billion dollars. Cinionic's Cinema-as-a-Service program enables minimal upfront capital investment required by AMC to bring Laser at AMC to moviegoers around the country," AMC stated.

12:00 EDT Gap falls -17.9% - Gap is down -17.9%, or -$2.56 to $11.73.

12:00 EDT A10 Networks rises 11.7% - A10 Networks is up 11.7%, or $1.54 to $14.74.

12:00 EDT Forge Global rises 33.4% - Forge Global is up 33.4%, or $3.91 to $15.61.

11:30 EDT Novo Nordisk announces positive scientific opinion from EMA on insulin storage - Novo Nordisk announced that the European Medicines Agency has granted the company a positive scientific opinion for a proposed update to the storage conditions of two human insulins. EMA's positive scientific opinion will now be used to support obtaining approval of the more flexible storage conditions by national health authorities in a number of relevant low- and middle-income countries. This to allow that Actrapid and Insulatard can be stored for four weeks outside of a refrigerator prior to use if there are six months or more to the expiry date. Once in use, the insulin should be stored without refrigeration. The new guidance aims to improve flexibility and convenience for many people with diabetes in low- and middle-income countries, who have limited access to reliable refrigeration, and who may live within long distances from a clinic or pharmacy.

11:25 EDT Roche reports CHMP recommends approval of Tecentriq as adjuvant NSCLC treatment - Roche announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Tecentriq as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adults with non-small cell lung cancer, or NSCLC, with a high risk of recurrence whose tumors express PD-L1 greater than or equal to 50% and who do not have EGFR mutant or ALK-positive NSCLC. A final decision regarding the approval of Tecentriq in this setting is expected from the European Commission in the near future, Roche said.

11:21 EDT Motive Capital Corp trading resumes

11:02 EDT Philips Respironics issues voluntary recall notifice for V60 ventilator family - Royal Philips announced that its subsidiary Philips Respironics is notifying customers of its V60/V60 Plus and V680 ventilators about a potential issue with the electrical circuit in these ventilators that controls the 35V power supply to the ventilator and alarm. Philips Respironics has already notified the relevant competent authorities. Philips Respironics has identified that there is a possibility that affected ventilator units may cease to operate, potentially without setting off an audible/visual alarm, a so-called "silent shutdown," and the patient may no longer receive respiratory assistance. Philips Respironics projects an average of less than one silent shutdown among one million uses per year. Philips Respironics is committed to addressing the issue and will provide regular updates to customers on the development of its plan to address the issue, with the first update to be provided before June 30, the company said. This is a voluntary recall notification for the U.S. only, and a field safety notice for the rest of the world. In the U.S., the FDA has classified the recall notification as a Class 1 recall, the company noted. In connection with this recall notification/field safety notice, Philips has taken a provision in the fourth quarter of 2021.

10:56 EDT LabCorp announces launch of 'Getlabs for Labcorp' test collection service - Labcorp announced the launch of "Getlabs for Labcorp," a health care service that combines Labcorp's diagnostic tests with Getlabs phlebotomy service to "conveniently test consumers in the comfort of their own homes" Amy Summy, executive vice president and chief marketing officer at Labcorp, said: "We want to make it easy for people to manage their health and this collaboration with Getlabs significantly expands Labcorp's home testing options to include our full range of tests. The blend of easy scheduling online, our full set of tests, and in-person testing makes it simple for individuals who want the convenience of at-home collection but are uncomfortable drawing their own blood or require diagnostic tests beyond those offered through Labcorp's at-home kits."

10:36 EDT ITT invests $2.5M in solar power lake in Barge, Italy - ITT announced the construction of a photovoltaic lake at its largest factory in Barge, Italy, as the company ramps up its sustainability investments to reduce its carbon footprint. Consisting of approximately 3,000 solar panels, the "lake" will be about the size of four Olympic swimming pools. The solar investment is expected to produce 1,065,200 kWh per year, covering 30% of the energy requirements for ITT's Motion Technology Innovation Center, where the company primarily conducts research and development activities to support brake pad technologies. The lake is expected to reduce CO2 emissions by 372.8 tonnes per year, equivalent to the CO2 emissions generated by about 42,000 gallons of gas. The project is scheduled to be completed by the end of 2022.

10:29 EDT Dogness Internationa trading resumes

10:18 EDT Amryt Pharma announces CHMP adopts positive opinion for Filsuvez - Amryt is pleased to announce that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the approval of Filsuvez in the European Union for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa in patients 6 months and older. EB is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. Based on this CHMP recommendation a decision by the European Commission is expected on the Filsuvez application within 67 days. The centralised marketing authorisation would be valid in all EU Member States as well as in Iceland, Liechtenstein, and Norway. The Medicines and Healthcare products Regulatory Agency in the UK is expected to grant authorisation within the same time period. The CHMP positive opinion is supported by Phase 3 data from the EASE trial which was the largest ever global trial conducted in patients with EB, performed across 58 sites in 28 countries. As a result of the CHMP positive opinion, the EMA Contingent Value Right issued to Amryt shareholders and option holders prior to the acquisition of Aegerion will now become payable. The quantum of the EMA CVR payable will be determined by the terms of the CVR Deed Poll and CVR holders will be notified in due course of their entitlement.

10:00 EDT Globus Medical falls -11.5% - Globus Medical is down -11.5%, or -$9.12 to $69.89.

10:00 EDT Gap falls -22.2% - Gap is down -22.2%, or -$3.17 to $11.12.

10:00 EDT Terran Orbital rises 10.2% - Terran Orbital is up 10.2%, or 47c to $5.10.

09:50 EDT LMF Acquisition Oppertunities Inc (Class A Stock) trading resumes

09:47 EDT American Realty Investors falls -13.4% - American Realty Investors is down -13.4%, or -$2.98 to $19.27.

09:47 EDT Carvana rises 8.1% - Carvana is up 8.1%, or $6.72 to $89.86.

09:47 EDT A10 Networks rises 12.1% - A10 Networks is up 12.1%, or $1.60 to $14.80.

09:42 EDT Novartis reports positive CHMP opinion for Tabrecta for METex14 NSCLC - Novartis announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion and recommended granting marketing authorization of Tabrecta as a monotherapy for the treatment of adults with advanced non-small cell lung cancer, or NSCLC, harboring alterations leading to mesenchymal-epithelial-transition factor gene exon 14, or METex14, skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

09:36 EDT Vuzix receives follow-on order for Vuzix Blade Smart Glasses - Vuzix Corporation announced an additional follow-on volume order of Vuzix Blade Smart Glasses from Medacta in connection with that company's launch of their NextAR shoulder augmented reality surgical platform in Europe and the US.

09:34 EDT Security Federal Corp to participate in Emergency Capital Investment Program - In early March 2021, the United States Department of Treasury announced it would invest $9 billion in Community Development Financial Institutions and Minority Depository Institutions through the Emergency Capital Investment Program. ECIP will provide up to $9 billion in capital directly to depository CDFIs and MDIs to support the provision of loans, grants, and forbearance for small and minority businesses and consumers in low income and underserved communities. As a qualified CDFI Bank serving communities in South Carolina and Georgia, Security Federal Corporation applied for an allocation of ECIP funds. On December 14, 2021, Security Federal was included on the Treasury's list of 186 financial institutions approved to receive ECIP investments. On April 21, 2022, the Board of Directors of Security Federal Corporation, the holding company of Security Federal Bank voted to move forward with an investment from the United States Department of Treasury under the Emergency Capital Investment Program. The Treasury had informed the Company that it is eligible to receive an ECIP investment in an amount up to $82,949,000 in the form of non-dilutive Tier 1 senior perpetual preferred capital. In connection with the ECIP investment from the Treasury, the Company would be required to fulfill certain conditions established by the Treasury and would be subject to certain restrictions.

09:27 EDT II-VI signs renewable energy contracts for nine U.S. sites - II-VI Incorporated announced that it has signed renewable energy contracts for powering nine of its sites in the United States with 100% renewable electricity. These new agreements represent 20 million kWh of renewable electricity per year, thereby avoiding an additional 5,000 metric tons of CO2 emissions annually. II-VI has set as a top priority to reduce its carbon footprint across its global operations. Including today's announcement, II-VI has entered into renewable electricity contracts for over 30 sites around the world, including more than two dozen that now cover 100% of their annual electricity usage with renewable sources. The sites announced today range from some of II-VI's most advanced manufacturing sites and some small engineering offices to multiple facilities across the U.S. in California, Oregon, New Jersey, and New York. II-VI announced in October 2021 that it is powering all of its facilities in Europe with 100% renewable electricity sources, and in January 2022 that its largest plant in China would be powered with 100% renewable electricity sources within four years.

09:25 EDT Nucor, University of Kentucky receive federal grant for carbon capture R&D - Nucor is partnering with the University of Kentucky Research Foundation to test an innovative carbon dioxide capture system at Nucor Steel Gallatin. This is one of 12 research projects being funded by a Department of Energy grant to advance point-source carbon capture and storage technologies that can capture CO2 emissions generated from natural gas power plants and industrial facilities which produce commodities like cement and steel. Once this pilot is complete Nucor and UK will have a better understanding of the costs and effectiveness of carbon capture technology for flue gas with low CO2 content and the feasibility of replication of this technology at other electric arc furnace steel mills.

09:07 EDT Meritage Homes partners with Arbor Day Foundation - In celebration of Earth Day today, and in alignment with its ESG objectives, Meritage Homes announces its partnership with the Arbor Day Foundation to support urban tree populations. To kick off the partnership, Meritage and the Arbor Day Foundation will host 18 regional tree planting and distribution events in 2022 across Meritage's footprint, including Arizona, California, Colorado, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Texas. During the spring and fall planting seasons, Meritage employees and community members will volunteer across the country to plant and distribute more than 1,300 trees in an effort to build more beautiful and environmentally resilient neighborhoods through improved tree canopy and greenspace. These projects will focus on areas that have been impacted by a variety of environmental and economic factors, such as storms, invasive species, urban heat island effect, low-income status, and environmental inequity.

09:05 EDT WISeKey, Porrima.CH team to launch sustainable NFT project - WISeKey International announced that it has teamed up with Porrima.CH for a first ever-sustainable NFT project using the Porrima.CH solar panels installed in 2010. Each solar panel is encased in a special cover that protects the panels from sea water. There are 800 panels - and these are the ones that undertook the world's first tour around the world using only solar energy. Each solar panel NFT will be auctioned off with a starting price of $2,222 each with an option also to acquire the physical serialized version with the microchip for $10,000. Collectors can have as an option to own both, the digital NFT plus the correspondent physical item. This will finance the refit for a next generation of solar panels. The first 100 panels are offered for NFT tokenization, which will be announced on April 22, 2022, on Earth Day. "The WISeKey NFT platform is secured by WISeKey's various security technologies enabling the authentication of digital identity based NFTs, physical objects as well as digital assets, in a safe end-to-end process. The user is in full control of its WISeID NFT and other NFTs need to request access to its identity information so WISeID NFTs users can decide by themselves what level of information they wish to share, thus keeping full control... As interest in NFTs continues to accelerate, WISeKey is committed to promoting a more environmentally friendly consumption and distribution model," said Carlos Moreira, Founder and CEO of WISekey.

09:03 EDT LMF Acquisition Opportunities, SeaStar Medical enter merger agreement - SeaStar Medical and LMF Acquisition Opportunities announced they have entered into a merger agreement. The transaction is expected to provide SeaStar Medical with access to the capital markets and thereby position the company to accelerate the development and advancement of its lead programs for acute kidney injury in both pediatric and adult patients, as well as advance other SeaStar Medical programs in acute and chronic indications. SeaStar Medical's Selective Cytopheretic Device is a patented, cell-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to address hyperinflammation. Neutrophils and monocytes are the cellular mediators that drive systemic inflammation, which when spreading uncontrollably through the body can lead to organ damage, organ failure or death. The SCD technology targets the cellular drivers of inflammation to restore balance in the body and potentially reverse the damage. SeaStar Medical intends to submit SCD for approval with the FDA under the Humanitarian Device Exemption to commence commercialization for the treatment of pediatric AKI and advance SCD into a pivotal trial for treatment of AKI in adults. The combined company will be known as SeaStar Medical Holding Corporation and will operate under the same management team as SeaStar Medical, which is led by Mr. Schlorff. The transaction contemplates an enterprise value of approximately $85 million for SeaStar Medical. As part of the transaction, all SeaStar Medical shares owned by SeaStar Medical's existing equity holders will be converted into Class A Common Stock of SeaStar Medical Holding Corporation. The Dow Chemical Company Pension Plans, as existing investors of SeaStar Medical, are committed to further participate in the transaction through a PIPE investment that is expected to close at the time of the completion of the business combination. The transaction has been unanimously approved by both Boards of Directors of SeaStar Medical and LMAO and is subject to approval by stockholders of LMAO and other customary closing conditions. The holders of a majority of the SeaStar Medical voting power have approved the merger. The proposed business combination is expected to be completed in the third quarter of 2022. Maxim Group LLC served as sole financial advisor to SeaStar Medical in connection with the proposed business combination. Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection with the proposed business combination.

09:02 EDT DuPont joins Apple Supplier Clean Energy Program - DuPont (DD) announced it has joined Apple's (AAPL) Supplier Clean Energy Program. By participating in the program, DuPont has committed to use 100 percent renewable electricity, including renewable energy credits in its manufacture of all products for Apple - a key milestone in achieving renewable electricity and climate stewardship goals outlined in DuPont's 2030 Sustainability Goals.

09:01 EDT DuPont says Kevlar, Nomex and Tyvek to be produced using renewable electricity - DuPont announced that its iconic and trusted brands, Kevlar, Nomex and Tyvek, will be produced using renewable electricity in its operations. DuPont achieved this milestone by purchasing renewable energy credits earlier this month to match the energy consumed in its 2022 operations and is committed to additional purchases annually. This underscores the company's commitment to achieving its renewable energy goal and acting on climate stewardship as part of its 2030 Sustainability Goals.

08:37 EDT Minim partners with USI Sales to expand sales footprint - Minim, creator of intelligent networking products under the Motorola brand, announces that it has partnered with USI Sales on a path to expand its sales footprint to potential in-store placements in office retailers. "As 25% of professional jobs in North America are expected to be remote by the end of this year, we believe office retailers are promising partners to serve consumers with high-quality home office network upgrades," said Jeff Rodning, Minim National Retail Sales Director. As part of the partnership, USI Sales will be able to offer their partner retailers Motorola intelligent networking solutions in the mesh, cable modem, and gateway categories. Motorola networking devices also feature the motosync app, powered by Minim, giving consumers access to parental controls, malware protection, ad block, performance testing, and live chat support.

08:36 EDT Navitas Semiconductor's GaN IC drives vivo's foldable phone - Navitas Semiconductor officially announced that its next-generation GaNFast power ICs with GaNSense technology have been selected to power vivo's newly-released, first folding-screen flagship 'X Fold' in-box 80W flash charger. The vivo X Fold adopts a high-capacity 4,600 mAhr dual-battery solution charging 0-50% in 17 minutes, and fully-charged to 100% in 37 minutes. "Navitas is honored that vivo's first foldable phone has an in-box GaNFast charger," said Gene Sheridan, Navitas' CEO and co-founder. "We sincerely congratulate vivo for their remarkable success in launching this excellent foldable phone. Our mission is to "Electrify Our World", and as every GaN IC shipped saves 4 kg of CO2, together we will achieve a faster, lighter, more efficient and more environmentally-friendly charging future."

08:33 EDT Salarius Pharmaceuticals announces $2.3M registered direct offering - Salarius Pharmaceuticals announced that it has entered into definitive agreements with several institutional investors for the purchase of 9,339,436 shares of its common stock, at a purchase price per share of $0.25, for gross proceeds of approximately $2.3 million, in a registered direct offering. Ladenburg Thalmann & Co Inc. is acting as the exclusive placement agent for the offering. The gross proceeds to Salarius, before deducting placement agent fees and other offering expenses, are expected to be approximately $2.3 million. Salarius intends to use the net proceeds from this offering for the continued clinical and pre-clinical development of its product candidates, and for other general corporate purposes. Additionally, Salarius has agreed to issue to the investors unregistered warrants to purchase up to 7,004,578 shares of common stock, with an exercise price of $0.3399. The warrants will be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. The closing of the offering is expected to take place on or about April 26, 2022, subject to the satisfaction of customary closing conditions.

08:32 EDT GlobalFoundries announces HSR waiting period expiration for sale of NY facility - GlobalFoundries announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 - HSR -, for onsemi's proposed acquisition of GF's East Fishkill, NY site and fabrication facilities announced in 2019. The expiration of the HSR waiting period satisfies all of the necessary regulatory requirements and the transaction is on track to close at the end of 2022 as planned.

08:31 EDT Quanterix granted Breakthrough Device designation by the FDA for Simoa - Quanterix announced that its Simoa neurofilament light chain, or NfL, plasma test has been granted Breakthrough Device designation by the FDA as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting MS, or RRMS. The FDA's breakthrough device designation is granted to products that have the potential to offer more effective diagnosis or treatment of life-threatening diseases with an unmet medical need. The program is designed to enable accelerated development, assessment and review processes, with the intention to provide patients with more timely access to breakthrough technologies or devices. However, breakthrough device designation does not guarantee that the FDA review and approval process will be shortened or that an application will be approved.

08:12 EDT BioLexis reorganization results in GMS as largest shareholder in Outlook - Outlook Therapeutics and BioLexis announced that BioLexis is being reorganized. The BioLexis reorganization, which does not entail any changes in the indirect ownership of Outlook Therapeutics, provides GMS Holdings with increased flexibility to support the future growth of Outlook Therapeutics as its largest shareholder. Pursuant to an agreement among BioLexis, GMS Ventures & Investments, and certain of GMS V&I's affiliates, on April 21, 2022, GMS V&I has taken direct ownership of all of the shares of Outlook Therapeutics that were indirectly owned by GMS Holdings through BioLexis. As the next step in the reorganization, GMS Holdings will cease to be a shareholder in BioLexis and BioLexis will be renamed "Tenshi Healthcare Pte Limited." GMS Holdings does not have an economic interest in, or voting rights with respect to, the shares of Outlook Therapeutics that are held by BioLexis.

08:12 EDT Lifeist Wellness announces public awareness initiative - Lifeist Wellness announced an initiative to raise public awareness of Lifeist and to promote the sale of Mikra products. FMW Media Works' New to The Street TV will feature Lifeist on its national and international syndicated television program with management introducing the Company to TV anchors and viewers. The series will span twelve months and will follow the Company's wellness journey and showcase wellness products emerging from its wholly owned subsidiary Mikra, Cellular Sciences, including its new novel cellular therapeutic compound, CELLF and upcoming athletic-focused, cellular product in collaboration with six-time MLB All-Star and Olympic Bronze medalist, Jose Bautista. FMW Media Works will produce and broadcast the show and commercial ads across all New to The Street syndicated televised platforms on Newsmax, FOX Business Network, and Bloomberg TV. All broadcasted shows will stream for 18 months on the New to The Street website. The Company announced that it has engaged Oak Hill Financial to provide targeted investor outreach and capital markets advisory services to the Company pursuant to a services agreement between the parties. Under the terms of the Services Agreement, the consideration payable by Lifeist to Oak Hill for the provision of the services during the initial six months of the term of the Services Agreement, being approximately $72,000 plus applicable taxes, and thereafter rolling to a monthly term terminable on 30 days notice at $12,000 per month plus applicable taxes. In addition, the Company intends to issue 250,000 options at the next available grant date, at an exercise price equal to the closing price per Company share on the TSXV on the day before the grant date, with the options vesting quarterly in four equal tranches and vested options expiring 24 months from the grant date irrespective of the status of the Services Agreement. The issuance of the Options is subject to the approval of the Board and is subject to the limitations provided by the Company's stock option plan and TSXV policies. Oak Hill currently has no direct or indirect interest in the securities of the Company, or any right or intent to acquire such an interest. The engagement of Oak Hill as an investor relations service provider of the Company remains subject to approval of the TSXV.

08:09 EDT Jasper Therapeutics to host KOL webinar on heamtopoietic stem cell therapies - Jasper Therapeutics announced that it will host an in-person key opinion leader webinar on transforming the field of hematopoietic stem cell therapies on April 28, 2022, at 1:00 p.m. ET. The webinar will feature presentations from KOLs Lori Muffly, M.D., M.S. of Stanford University and David Sallman, M.D. of Moffitt Cancer Center. During the presentation, Dr. Muffly and Dr. Sallman will provide an overview of the current landscape and unmet medical need in hematopoietic stem cell transplant conditioning as well as myelodysplastic syndromes treatment. Members of the Jasper Therapeutics management team will discuss how JSP191, a targeted, monoclonal antibody currently in clinical development as a conditioning agent, may address the limitations of transplant conditioning. Additionally, management will demonstrate the potential new therapeutic approach for JSP191 in disease modification for lower-risk MDS patients.

08:07 EDT Sylvamo adopts shareholder rights plan following Atlas block trade - Sylvamo's board of directors unanimously adopted a limited-duration shareholder rights plan. The rights plan is effective immediately. The board adopted the plan after Atlas Holdings confirmed it entered into a block trade that would give Atlas nearly 14% of Sylvamo's outstanding shares and informed Sylvamo it also holds an unspecified amount of derivatives on Sylvamo shares. Sylvamo's leaders maintain open dialogue with Sylvamo's investors, including Atlas, and plan to continue these conversations. The rights plan reduces the likelihood any person or group could gain control of the company through open market or private accumulations of our shares without appropriately compensating shareholders for such control or providing the board sufficient time to make informed decisions. The rights plan applies equally to all current and future shareholders; it does not deter offers or prevent the board from considering offers that are in the best interest of Sylvamo shareholders. In light of, among other things, recent market volatility and Sylvamo's March 7 announcement regarding its business in Russia, Sylvamo does not believe the current market price reflects its intrinsic value. Sylvamo is issuing one right for each share of common stock outstanding as of the close of business May 2. The rights will initially trade with Sylvamo common stock and will generally become exercisable only if any person acquires 10% or more of Sylvamo's outstanding common stock, except that any person or group who currently owns more than the triggering percentage may continue to own shares of common stock. However, any current owner of more than the triggering percentage may not acquire any additional shares without triggering the rights plan. The rights plan does not combine the ownership of shareholders "acting in concert" unless they have formed a group under applicable securities laws. If the rights become exercisable, all holders will be entitled to acquire shares of common stock at a 50% discount, or Sylvamo may exchange each right held by such holders for one share of common stock. The plan does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future board of directors to redeem the rights. The rights plan has a one-year term, expiring April 21, 2023. However, the board may consider an earlier termination as circumstances warrant.

08:06 EDT Sunrun releases 2021 Impact Report - Sunrun released its 2021 Impact Report, accelerating progress and setting ambitious goals for leading on Environmental, Social and Governance initiatives. Notable achievements include providing over $800 million in energy cost savings to customers; increasing gender and Black, Indigenous, and People of Color representation throughout the company; and Sunrun solar systems generating 20 billion kilowatt-hours of clean energy since 2007, helping avoid approximately 11.2 million metric tons of carbon dioxide equivalent-the equivalent of taking 2.4 million cars off the road for a year. The 2021 Impact Report details Sunrun's recent efforts in priority areas such as talent attraction, retention, development, advancing diversity and inclusion initiatives, employee safety, as well as ways the company is delivering value to its customers through the electrification of homes and transportation. Furthermore, the Report spotlights Sunrun's commitment to adopt science-based emissions reduction targets. Additional highlights from Sunrun's 2021 Impact Report include: Updated Sustainability Goals for 2022 and Beyond: In the company's 2020 Impact Report, Sunrun unveiled its initial corporate sustainability goals focused on mitigating the impacts of anthropogenic climate change; building a diverse, fair and equitable workforce; and improving environmental equity and justice. As part of its commitment to annual reporting, the 2021 Impact Report highlights Sunrun's progress towards those goals as well as ESG updates to improve outcomes. Updated goals include: Decrease transportation emissions by transitioning half of the company's vehicle fleet to either electric or hybrid by the end of 2025. Achieve 100% equipment recycling at each operating facility by the end of 2023. Foster a diverse workforce that represents the customers and communities in which the company's employees live and work by: Increasing the representation of employees who identify as women in Director and above roles by 50% and increasing the representation of BIPOC leaders in Manager roles by 25% by the end of 2025. Reaching gender parity in Director and above roles and BIPOC representation parity in Manager roles by the end of 2030.

08:04 EDT Scynexis announces interim data from Phase 3 FURI, CARES studies - SCYNEXIS announced positive interim data from its ongoing Phase 3 FURI and CARES studies. The ongoing Phase 3 open-label, single-arm FURI study is evaluating oral ibrexafungerp for the treatment of patients with severe fungal infections who are either intolerant to standard antifungal therapy or experience refractory fungal infections despite treatment. The CARES study, also an ongoing Phase 3 open-label, single-arm trial, is evaluating oral ibrexafungerp in patients with systemic infections caused by C. auris, an organism that is often multi-drug resistant, associated with high mortality and classified by the U.S. Centers for Disease Control and Prevention as an "Urgent Threat" to public health. Of the 131 FURI and CARES study cases analyzed to date, 61.1% achieved a complete or partial response, or clinical improvement; 22.1% achieved stable disease, which is a favorable outcome in patients with severe progressive fungal infections; 11.5% were considered no response, which includes two patients who died of an underlying condition unrelated to the treatment; and 5.3% were considered indeterminate. "We are extremely pleased to share these new positive interim analyses from our ongoing FURI and CARES studies, which continue to demonstrate the ability of ibrexafungerp to be a powerful tool in the fight against a broad range of serious and potentially deadly infectious diseases," said Marco Taglietti, M.D., President and CEO of SCYNEXIS. "This research is a key part of our efforts to build a broad antifungal franchise to help treat millions of patients struggling with severe fungal infections." The fourth interim analyses included 39 new cases from FURI and eight new cases from CARES who completed treatment during the 12 months since the prior interim analyses. Results were consistent with previously reported data and support continued patient enrollment in both studies. SCYNEXIS will present additional details from these interim analyses at the 32nd European Congress of Clinical Microbiology and Infectious Diseases being held in Lisbon, Portugal, April 23-26, 2022.

08:03 EDT Ultragenyx appoints Amrit Ray to board of directors - Ultragenyx Pharmaceutical (RARE) announced the appointment of Amrit Ray, M.D., M.B.A. to the company's Board of Directors. Dr. Ray will serve on the Board's Research and Development Committee. Ray is Chief Patient Officer for Biohaven Pharmaceuticals (BHVN), a commercial-stage biopharmaceutical company focused on neurological and neuropsychiatric diseases.

08:01 EDT Benefitfocus names Kristin Adams as Chief People Officer - Benefitfocus (BNFT) announced Kristin Adams as Executive Vice President and Chief People Officer. Effective immediately, Adams will lead the company's people strategy with a focus on talent acquisition, development and retention; corporate culture; diversity, inclusion and belonging; employee compensation and benefits and organizational structure. Adams is a full-scale talent advisor with a proven track record of scaling and managing teams. She spent more than 20 years at Morgan Stanley (MS) in various leadership roles where she helped lead future of work initiatives designed to catapult the company into its next phase.

07:54 EDT Cleveland-Cliffs jumps 7% to $31.75 after Q1 results beat estimates - The company also raised its 2022 average selling price expectation.

07:44 EDT Guardian Capital becomes founding member of the Pond Foundation - Guardian Capital Group announcedthat it has joined The Pond Foundation as a founding member. The Pond Foundation is a non-profit organization whose mission is to change the way the world acts on climate change. Their signature climate action program, My Carbon Zero, was created to inspire people and organizations to take their own strong, credible climate action. As part of this partnership, Guardian and all of its subsidiaries will balance their annual carbon emissions from 2022 onwards, both by reducing their own emissions and by investing in external, nature-based projects which remove carbon from the atmosphere.

07:38 EDT Verizon reports Q1 Consumer wireless retail postpaid net losses of 292K - Total Verizon Consumer revenue for the quarter grew 10.9 percent year over year, driven by the first full quarter of TracFone integration, higher equipment revenue, and strong core wireless service revenue growth. Total Verizon Consumer revenues were $25.3 billion. Wireless service revenue was up 11.2 percent year over year. In addition to the inclusion of TracFone, Postpaid ARPA increased 2.6 percent driven primarily by step-up momentum and growth within non-connectivity products and services. Verizon Consumer ended the quarter with 36 percent of its account base on a premium tier. Verizon Consumer wireless retail postpaid churn was 0.95 percent in first-quarter 2022, and wireless retail postpaid phone churn was 0.77 percent. While churn was steady, the competitive dynamics within the industry resulted in wireless retail postpaid phone net losses of 292,000, due to a decline in gross additions of 2 percent from prior year. Verizon Consumer had fixed wireless net additions of 112,000 for the quarter, with sales boosted by Verizon's launch of C-Band spectrum and "5G Ultra" campaign. Additionally, Fios internet net additions for the quarter were 55,000, driven by record-low churn levels with gross additions lower compared to first-quarter 2021. Verizon Consumer Fios revenues were $2.9 billion in first-quarter 2022, an increase of 1.8 percent year over year. Verizon Consumer reported 78,000 Fios Video net losses in first-quarter 2022. Prepaid ARPU in the quarter was $30.89 across all of Verizon Consumer's prepaid brands. This decline over first-quarter 2021 results was driven, in part, by pressure in the TracFone brands, though prepaid ARPU is expected to stabilize and subsequently grow sequentially as we execute our strategy to bring additional value to our customers.

07:38 EDT Kimberly-Clark CEO says taking 'necessary actions to mitigate macro headwinds' - "I'm pleased with our team's continued excellent execution during this volatile and highly inflationary environment. We delivered double-digit organic sales growth with strong increases across all our segments in the first quarter," said Chairman and CEO Mike Hsu. "Our growth strategy is working and we're continuing to invest in our business. Additionally, we continue to take the necessary actions to mitigate macro headwinds and remain committed to improving our margins over time."

07:36 EDT Verizon reports Q1 Broadband net additions 229,000 - 229,000 total broadband net additions, the best quarter in over a decade, including 194,000 fixed wireless net additions, 2.5 times the fourth quarter 2021 level. 35,000 wireline broadband net additions, driven by 60,000 Fios Internet net additions in first-quarter 2022.

07:35 EDT Blueknight Energy Partners to be acquired by Ergon - Blueknight Energy Partners announced that it has entered into a definitive agreement and plan of merger pursuant to which an affiliate of Ergon would acquire all of the outstanding common and preferred units of the Partnership not already owned by Ergon and its affiliates. The agreement follows the offer made by Ergon in October 2021 to acquire the Public Common Units and Public Preferred Units. The agreement provides for an all-cash transaction, whereby: each holder of the Public Common Units would receive $4.65 per common unit owned; and each holder of the Public Preferred Units would receive $8.75 per preferred unit owned. The Board of Directors of Blueknight Energy Partners G.P., the general partner of Blueknight, delegated to a conflicts committee of the GP Board, BKEP Conflict Committee. The BKEP Conflicts Committee, after evaluating the transaction with its independent legal and financial advisors, unanimously approved the transaction on behalf of the holders of the Public Common Units. The transaction is expected to close in mid-2022, subject to customary approvals. Ergon has committed to vote its units to approve the transaction.

07:33 EDT CloudMD announces resignation of Kohler as director, chair of the board - CloudMD Software & Services announces that Mark Kohler has resigned as a director of the Company and the Chair of the Board, effective April 21, 2022, for personal reasons.

07:26 EDT Establishment Labs presents data from Motiva U.S. IDE stud - In a press release issued last night, the company stated: "Establishment Labs noted the presentation of interim study data from the augmentation cohort of its Motiva US IDE Study. This Study Update includes two-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also a Principal Investigator in the Study, is presenting the results today at The Aesthetic Meeting 2022 in San Diego, California. Dr. Glicksman will present data for the 451 primary augmentation patients enrolled in the study through the two-year follow-up visit. Patient compliance in the primary augmentation cohort of the trial at two years was 94.9%." Commenting on the results, Dr. Glicksman said, "The Motiva IDE study is still in its follow-up phase, but the high rate of patient follow-up and preliminary clinical results are encouraging. The clinical study data we will present today adds to a foundation of science and clinical data on Motiva Implants going back eleven years and encompassing over two-million implants. As a study investigator on this rigorous PMA Study, I am proud to be a part of providing women in the United States access to a new class of options in breast implants."

07:15 EDT Gatos Silver receives noncompliance notice from NYSE - Gatos Silver announced that it received a notice from the New York Stock Exchange stating that the company was not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission.

07:07 EDT XPO Logistics introduces 'Ship Net-Zero with truck brokerage business - XPO Logistics has introduced a carbon-offset shipping option for customers of its truck brokerage business in North America. The company's Ship Net-Zero with XPO program gives shippers a way to negate the carbon footprint of their freight by purchasing carbon offsets for the sustainability project of their choice. Drew Wilkerson, XPO's president of North American transportation, said, "We developed our Ship Net-Zero program to make a climate-positive impact today, while the transportation industry transitions to hybrid and zero-emission heavy vehicles over time. Ship Net-Zero gives our brokerage customers a meaningful, documented way to offset the emissions of their shipping activities. Carbon investing can reduce the carbon footprint of freight movements to zero by funding sustainability projects that align with personal values or corporate goals."

07:06 EDT Newmont expects increasing gold production - The company said, "Newmont's outlook reflects increasing gold production and ongoing investment in its operating assets and most promising growth prospects. Outlook includes current development capital costs and production related to Tanami Expansion 2, Ahafo North, Yanacocha Sulfides, Pamour at Porcupine and Cerro Negro District Expansion 1. Newmont continues to develop our mine plan utilizing a $1,200 per ounce gold price assumption. However, due to sustained higher gold prices over the last two years, Newmont's 2022 outlook assumes an $1,800 per ounce revenue gold price for CAS and AISC to reflect higher costs from inflation, royalties and production taxes. In 2022, an additional 5% of cost escalation is incorporated into our direct operating costs related to labor, energy, and material and supplies. 2022 and longer-term outlook assumes a $30 per ounce impact from production taxes and royalties attributable to higher gold prices. Outlook assumes operations continue without major Covid-related interruptions. Newmont continues to maintain wide-ranging protective measures for its workforce and neighboring communities, including screening, physical distancing, deep cleaning and avoiding exposure for at-risk individuals, which are expected to impact AISC per gold equivalent ounce by approximately $10 per ounce. If at any point the Company determines that continuing operations poses an increased risk to our workforce or host communities, it will reduce operational activities up to, and including, care and maintenance and management of critical environmental systems. Please see the cautionary statement for additional information."

07:06 EDT CareDx announces presentations of data on AlloHeme, AlloCell - CareDx (CDNA) - The Transplant Company announced the presentation of new data during the Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR being held on April 23-26 in Salt Lake City, Utah, highlighting the capabilities of AlloHeme and AlloCell for allogeneic cell transplant and therapy monitoring. CareDx will also share information about its OTTR Patient Management Software that has recently been validated to SMART, Substitutable Medical Applications, Reusable Technologies, on FHIR, Fast Healthcare Interoperability Resource, standards and is available for customer use. Data being presented: Title: "AlloCell Provides a Highly Accurate, Sensitive, and Universal Solution for Monitoring Expansion and Persistence of Allogeneic Cellular Therapies." This abstract shows that AlloCell is a highly sensitive and precise method for universal detection and quantification of engineered and non-engineered allogeneic cell therapies. Title: "Advances in Chimerism Monitoring Using NGS Technology - Design of the ACROBAT Multicenter Clinical Trial" This abstract highlights the prospective, multi-center, observational clinical trial designed to evaluate the role of AlloHeme testing to monitor for relapse in patients post allo-HCT. Title: "Analytical Evaluation and STR Comparison of the Accurate and Sensitive Microchimerism Monitoring Tool for Relapse Prediction Post-Allogeneic HCT." This abstract highlights the analytical performance of AlloHeme and demonstrates the high accuracy and sensitivity of AlloHeme in detecting chimerism compared to short tandem repeat. Title: "SMART on FHIR Aligns an EHR with the Transplant-Specific Database." This abstract highlights the collaboration between CareDx and Cerner (CERN) to develop and validate the CareDx OTTR software to support transplant data electronic health record integration in line with public SMART/FHIR API user interface standards.

07:02 EDT Balchem releases 2021 sustainability report - Balchem Corporation released its 2021 Sustainability Report, which captures the Company's commitment to managing Environmental, Social and Governance performance. The company said, "Balchem's sustainability initiatives are fully integrated into our business strategy and are critical to our vision of making the world a healthier place. Our Sustainability Report demonstrates the Company's continuing promise to provide our employees, customers, shareholders and the communities within which we operate with information on Balchem's sustainability initiatives. Highlights of the report include: We celebrated the one-year anniversary of our commitment to the UN Global Compact, confirming our alignment with the Ten Principles on human rights, labor, the environment, and anti-corruption. Progress on our 2030 goals and strategies for both emissions and water usage reduction by 25%. The number of people and animals reached around the world by our health and nutrition products. Our continuous focus on employee safety and product quality. We took meaningful steps toward advancing diversity, inclusion, and belonging at Balchem, and remain committed to fostering a diverse and inclusive culture in which everyone feels welcomed, valued, and appreciated, while inspiring our external stakeholders to share our vision. Expanded our Balchem Helping Hands initiative which includes Balchem's philanthropic partnerships, a matching donation program, and an employee volunteering program. Additional transparency surrounding our initiatives in Governance, including Board Diversity and Risk Management. Newsweek magazine named Balchem one of America's Most Responsible Companies for the second consecutive year."

07:02 EDT Aaron's announces Executive Chairman Asbjornson to retire - AAON announced that Norman Asbjornson, Director, Executive Chairman and Founder of AAON, intends to retire from his position of Executive Chairman effective May 12, 2022, and will continue to serve as a member of the company's Board of Directors. In addition, Asbjornson will continue to assist the Company in a consulting and advisory role until May 2024.

06:52 EDT Schlumberger reports Q1 cash flow from operations $131M - Reflecting the seasonal increase in working capital.

06:48 EDT Stanley Black & Decker to sell Access Technologies to Allegion for $900M in cash - Stanley Black & Decker (SWK) announced it has signed a definitive agreement for the sale of its automatic doors business, Access Technologies, to Allegion (ALLE) for $900M in cash. The Access Technologies business generated approximately $340M in revenue in 2021 at a mid-teen adjusted EBITDA margin. Net proceeds from the sale are expected to be used to fund Stanley Black & Decker's previously announced share repurchase program as well as debt reduction. The company's overall capital allocation strategy reflects its commitment to generating substantial capital returns, maintaining strong investment grade credit ratings and pursuing opportunistic M&A. The transaction is subject to regulatory approval and other customary closing conditions. The company expects to record Access Technologies as discontinued operations when it reports first quarter results on April 28.

06:39 EDT AB InBev appoints Ricardo Tadeu as CGO - In a press release yesterday, the company said, "Anheuser-Busch InBev announced a newly aligned commercial leadership structure designed to accelerate the next phase of innovation and growth. Based in New York, Ricardo Tadeu, formerly Chief B2B Officer, has been appointed to the newly created role, Chief Growth Officer, reporting to AB InBev CEO, Michel Doukeris. This new structure will align marketing, sales, B2B and Direct-to-Consumer under Tadeu in his Chief Growth Officer role. As Chief Growth Officer, Tadeu's direct reports will include: Lucas Herscovici, formerly Chief Sales Officer, who will continue to serve on the senior leadership team, now as Chief Direct-to-Consumer Officer. Nick Caton, formerly the Chief Financial Officer for Anheuser-Busch will replace Tadeu as Chief BEES Officer and join the AB InBev SLT. Marcel Marcondes, most recently President of Beyond Beer and formerly Chief Marketing Officer of Anheuser- Busch, has been appointed Chief Marketing Officer of AB InBev and will join the AB InBev SLT. Marcondes replaces Pedro Earp who is leaving the company. Pablo Panizza, formerly Chief Direct to Consumer Officer, will transition to a new role as Global Head of Sales & Distribution. And Bernardo Novick, Global Head of ZX Ventures, will now report to Tadeu in this new structure." Reference Link

06:35 EDT AB InBev plans to sell interest in Russian JV, sees $1.1B impairment charge - The company said, "Anheuser-Busch InBev announced that it will sell its non-controlling interest in the AB InBev Efes joint venture and is in active discussions with its partner, Turkish Brewer Anadolu Efes, to acquire this interest. AB InBev's request regarding the suspension of the license for production and sale of Bud in Russia will also be part of a potential transaction. AB InBev previously announced it is forfeiting all financial benefit as a non-controlling partner from the joint venture operations. As a result, AB InBev is de-recognizing the investments in AB InBev Efes and will report a 1.1 billion USD non-cash impairment charge in non-underlying share of results of associates as part of its first quarter results announcement. Together with its partner, AB InBev continues to support its employees, their families and the humanitarian relief efforts in Ukraine. Support for its displaced employees and their families includes counseling, housing and financial support. In addition to donating to NGOs and the relief organization Caritas, AB InBev is working in partnership with them, other companies and local NGOs to provide food, blankets, medical supplies and 3 million cans of emergency drinking water to Ukraine and surrounding refugee relief areas. AB InBev has also introduced Chernigivske, Ukraine's most loved beer brand, to many countries, including the UK, Germany, Belgium, France, Netherlands, Denmark, Austria, Poland, Italy, Colombia and Brazil with additional markets planned. All profits from the sale of Chernigivske will go to support humanitarian relief efforts and AB InBev is guaranteeing at least 5 million USD of support from this humanitarian initiative. AB InBev's focus remains on assisting its people, their families and the overall humanitarian relief efforts while wishing for peace." Reference Link

06:33 EDT AZZ Inc. will not issue 2023 guidance at this time - Ferguson added, "Due to our recent announcement related to the acquisition of Precoat Metals, we will not issue fiscal year 2023 guidance at this time. However, based upon the evaluation of information currently available to management, excluding the impact of the pending Precoat acquisition, we anticipate Metal Coatings will exceed $150 million in sales and exceed 30% EBITDA for the first quarter of fiscal year 2023. We anticipate Infrastructure Solutions for the first quarter of fiscal 2023 will exceed their results in the first quarter of fiscal 2022. This reflects our best estimates given current market conditions, existing execution on our current backlog, and does not include the impact of acquisitions or divestitures, related expenditures, nor any federal regulatory changes that may emerge."

06:08 EDT WHO recommends Paxlovid COVID-19 therapy from Pfizer - In a World Health Organization press release, the organization said, "WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date. However, availability, lack of price transparency in bilateral deals made by the producer, and the need for prompt and accurate testing before administering it, are turning this life-saving medicine into a major challenge for low- and middle-income countries. Pfizer's oral antiviral drug is strongly recommended for patients with non-severe COVID-19 who are at highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients. This recommendation is based on new data from two randomized controlled trials involving 3078 patients. The data show that the risk of hospitalization is reduced by 85% following this treatment. In a high-risk group, that means 84 fewer hospitalizations per 1000 patients. WHO suggests against its use in patients at lower risk, as the benefits were found to be negligible. One obstacle for low- and middle-income countries is that the medicine can only be administered while the disease is at its early stages; prompt and accurate testing is therefore essential for a successful outcome with this therapy. Data collected by FIND show that the average daily testing rate in low-income countries is as low as one-eightieth the rate in high-income countries. Improving access to early testing and diagnosis in primary health care settings will be key for the global rollout of this treatment. WHO is extremely concerned that -- as occurred with COVID-19 vaccines -- low- and middle-income countries will again be pushed to the end of the queue when it comes to accessing this treatment. Lack of transparency on the part of the originator company is making it difficult for public health organizations to obtain an accurate picture of the availability of the medicine, which countries are involved in bilateral deals and what they are paying. In addition, a licensing agreement made by Pfizer with the Medicines Patent Pool limits the number of countries that can benefit from generic production of the medicine. The originator product, sold under the name Paxlovid, will be included in the WHO prequalification list today, but generic products are not yet available from quality-assured sources. Several generic companies are in discussion with WHO Prequalification but may take some time to comply with international standards so that they can supply the medicine internationally. WHO therefore strongly recommends that Pfizer make its pricing and deals more transparent and that it enlarge the geographical scope of its licence with the Medicines Patent Pool so that more generic manufacturers may start to produce the medicine and make it available faster at affordable prices. Along with the strong recommendation for the use of nirmatrelvir and ritonavir, WHO has also updated its recommendation on remdesivir, another antiviral medicine. Previously, WHO had suggested against its use in all COVID-19 patients regardless of disease severity, due to the totality of the evidence at that time showing little or no effect on mortality. Following publication of new data from a clinical trial looking at the outcome of admission to hospital, WHO has updated its recommendation. WHO now suggests the use of remdesivir in mild or moderate COVID-19 patients who are at high risk of hospitalization. The recommendation for use of remdesivir in patients with severe or critical COVID-19 is currently under review." Reference Link

06:02 EDT M.D.C. Holdings subsidiary to acquire homebuilding assets of The Jones Company - M.D.C. Holdings announced that its subsidiary, Richmond American Homes of Tennessee, has entered into an asset purchase agreement to acquire substantially all of the homebuilding assets of The Jones Company of Tennessee. Jones closed over 370 homes in fiscal year 2021 in the Nashville area with an average sales price of $564,000, generating revenues of $209M. MDC expects the transaction to close near the end of the second quarter of 2022, and it is expected to add approximately 10 selling communities, 1,700 controlled lots and 150 units in backlog to the operations of Richmond American. Consummation of the transaction is subject to the approval of the MDC board of directors and customary conditions.

05:50 EDT SAP backs FY22 cloud revenue view up 23%-26% - Sees FY22 effective tax rate 23%-27%. Sees FY22 free cash flow above EUR 4.5B. The company said, "For the fiscal year, we expect a total negative revenue impact of approximately EUR 300 million from lack of new business and discontinuation of existing business, in particular software and support and services. For non-IFRS operating profit we expect an impact of approximately EUR 350 million from the revenue gaps mentioned above and other expense items. In addition to the above, the company expects to incur restructuring expenses of approximately EUR 80-100 million for the fiscal year which will not affect non-IFRS results. Despite these headwinds, the cloud performance allows SAP to reaffirm its cloud revenue, cloud and software revenue as well as non-IFRS operating profit and free cash flow outlook. The reiteration of the non-IFRS operating profit outlook reflects the benefits of a continued strong cloud revenue growth, operational discipline and portfolio streamlining measures. Other impacts due to this rapidly evolving situation are currently unknown and could potentially subject our business to materially adverse consequences should the situation escalate beyond its current scope."

05:36 EDT Li Auto updates status under HFCAA - Li Auto updated its status under the Holding Foreign Companies Accountable Act, or HFCAA. The company was provisionally named by the United States Securities and Exchange Commission as a Commission-Identified Issuer on April 21, following the company's filing of the annual report on Form 20-F for the fiscal year ended December 31, 2021 with the SEC on April 19. The company understands that this identification under the HFCAA and its implementation rules issued thereunder indicates that the SEC determines that the company used a registered public accounting firm whose working paper cannot be inspected or investigated completely by the Public Company Accounting Oversight Board of the United States, or PCAOB, to issue the audit opinion for its financial statements for the fiscal year ended December 31, 2021. In accordance with the HFCAA, the SEC shall prohibit a company's shares or American depositary shares, or ADSs, from being traded on a national stock exchange or in the over-the-counter trading market in the United States if the company has been identified by the SEC for three consecutive years due to PCAOB's inability to inspect the auditor's working paper. The company has been actively exploring possible solutions to protect the interest of its stakeholders. The company maintains a dual-primary listing on The Main Board of The Stock Exchange of Hong Kong Limited under the stock code "2015." Its Class A ordinary shares and ADSs remain mutually fungible. The company will continue to comply with applicable laws and regulations in both China and the United States.